Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q1 2026 · 10-Q
Revenue$186.67M$186.67M+11.1% vs Q1 2025 Net Income-$17.11M-$17.11MN/M vs Q1 2025 EPS Diluted-$0.13-$0.13N/M vs Q1 2025 Gross Profit$80,864,000+10.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flow-$8,137,000N/M Free Cash Flowderived-$13,137,000N/M Margins · derivedGross margin43.3%−0.3 pt vs Q1 2025
Operating margin-9.8%+6.8 pt vs Q1 2025
Net margin-9.2%+6.3 pt vs Q1 2025
ended Mar 31, 2026 · filed Apr 28, 2026 · 28 d after period end